Cardiac medical device developer BioVentrix files for an $17 million IPO
IPO Overview
BioVentrix, a medical device firm developing minimally invasive treatments for heart failure, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.
BioVentrix is a medical device company developing and commercializing devices to treat heart failure with reduced ejection fraction （HFrEF）。 Its lead product, the Revivent System, is designed to restore left ventricular function in HFrEF patients with anterior wall scarring from prior myocardial infarction. The device uses titanium anchors connected by PEEK tethers to plicate scarred, non-functional myocardium and reduce left ventricular volume through a minimally invasive mini-thoracotomy procedure. The procedure is performed on a beating heart and is intended to provide a less invasive alternative to traditional open-heart surgical approaches such as ventricular assist device implantation or heart transplantation. BioVentrix previously generated revenue from the sale of its Revivent TC? TransCatheter Ventricular Enhancement System, which is stopped selling in 2023 to preserve capital.
The Mansfield, MA-based company was founded in 2003 and plans to list on the Nasdaq under the symbol BVXX. BioVentrix filed confidentially on August 5, 2025. The Benchmark Company is the sole bookrunner on the deal. No pricing terms were disclosed.
About the Company
We are a medical device company focused on developing, manufacturing and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction （“HFrEF”）。 Our lead device program, the Revivent System, has a CE mark in Europe and is in its pivotal trial in the United States. In Europe （where we have obtained approval but are currently not commercially operating in order to preserve capital） or through an authorized U.S. clinical site （as we have not received FDA approval）， heart failure specialists refer HFrEF patients with left ventricular dilation due to large anterior heart attack scars to cardiac surgeons who elect to utilize our product to restore left ventricular function by reducing the size of the left ventricle. The Revivent System accomplishes this reduction by folding the scar onto itself and fastening it together in a less invasive mini-thoracotomy procedure. The Revivent System is a less invasive surgical device designed to treat ischemic heart failure by excluding scarred anterior wall tissue in the left ventricle. /The Revivent System uses titanium anchors connected by PEEK tethers to plicate or fold non-functional myocardium scarred tissue onto itself, reduce LV volume and restore cardiac function. /The Revivent System can be implanted on a beating heart through a mini-thoracotomy in under 90 minutes, offering a less invasive alternative to heart transplants, ventricular assist devices, and other open-heart surgical approaches.